# Safety and Efficacy of Encapsulated Allogeneic MPS-1 Therapy

> **NCT05665036** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Sigilon Therapeutics, Inc.**

## Conditions studied

- MPS I
- MPS1-S
- MPS1-HS

## Interventions

- **COMBINATION_PRODUCT:** SIG-005 (hIDUA Producing Spheres)

## Key facts

- **NCT ID:** NCT05665036
- **Lead sponsor:** Sigilon Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11-15
- **Primary completion:** 2022-12-13
- **Final completion:** 2022-12-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor developing new product
- **Last updated:** 2023-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05665036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05665036, "Safety and Efficacy of Encapsulated Allogeneic MPS-1 Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05665036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*